Additional biomarkers may help colorectal cancer testing

10/19/2009 | Medscape (free registration)

Testing patients with metastatic colorectal cancer for their KRAS status plus three other biomarkers could nearly double the identification rate of people who likely will not respond to anti-epidermal growth-factor receptor targeted therapy, Italian researchers reported. The additional biomarkers, however, need further testing and are not ready for clinical use, one expert said.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX